Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06600802Not ApplicableRecruiting

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

Role: collaborator

NCT07085624Not ApplicableNot Yet Recruiting

Early Optimization of Ceftazidime Regimen in Critical Care

Role: collaborator

NCT05710679Not ApplicableRecruiting

Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer

Role: collaborator

NCT06893900Not Yet Recruiting

Assessing Shoulder Pathways Involving the Cuff

Role: collaborator

NCT04649086Not ApplicableTerminated

Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection

Role: collaborator

All 5 trials loaded